Humira Archives - DelveInsight

Humira

pharma-news-for-sandoz-agios-organon-bms-sanofi-bayer-lilly
Sandoz’s Generic Revlimid; Agios’ Pyrukynd; Organon Announces 4Q & Full-year Earnings ...

Sandoz Launches generic Revlimid in 19 European Countries, Bringing a Flood of Competition to BMS' Megablockbuster Since Bristol Myers Squibb acquired Celgene and its megablockbuster Revlimid, ...


biosimilar-market-outlook
Analyzing the Growth of the Biosimilar Market Through Years

The expiration of many biologic drugs patents has sparked biosimilar development and boosted the biosimilar market growth. Biosimilars are alternative versions of innovator biologic drugs. These a...


vedanta
Prometic bags $50M; Vedanta receives $12M; Humira biosimilar deal

Prometic bags USD 50 Million stock sale option to ease a cash crunch Prometic Life Sciences got into an agreement for selling USD 50 million in stock. This gives Prometic a way to escape its curren...


EMA to relocate to Amsterdam; Roche’s prospects; Amgen’s Humira Biosimilar delayed; Purdue’s opio...

EMA to relocate to Amsterdam by March 2019 Results of the Monday's vote for the European Medicines Agency relocation led to the emergence of Amsterdam as the new headquarters, beating the other fin...


Notizia
Idera’s Phase I Data; DelMar Initiates Trial; Novartis’ study; Humira gets EC approval

Idera Pharmaceuticals Present Positive Phase I Data for their Drug candidate IMO-2125 Idera Pharmaceuticals announced final results from the dose-selection phase of an ongoing Phase 1/2 trial inves...


Gilead faces lawsuit; Herceptin stalled; Lilly revs up, Abemaciclib gets nod; Key Humira patent g...

Gilead faces revived lawsuit claiming it sidestepped FDA with HIV drug imports Gilead Sciences thought it had prevailed in a whistleblower lawsuit alleging it circumvented FDA rules to use a China-...


Humira’s patent; Teva laying off; GSK aims; Thermo acquires Patheon; J& J’s Invokana

Key Humira patent goes down via IPR—but biosims makers shouldn't celebrate yet One of AbbVie’s Humira patents bit the dust late Tuesday, marking a win for biosimilars makers. But they still have a ...


Cancer, diabetes and eczema on list; AbbVie’s Humira; Teva weighs $2B; Fresenius in buyout ...

Cancer, diabetes and eczema star in 2017 top-launch list Launch prognostications are getting more attention than ever as they come out with “Drugs to Watch” list, and the highlights of different dr...


Taltz (Ixekizumab) in Treatment of Plaque psoriasis

Plaque psoriasis is a chronic autoimmune condition, with a buildup of dead cells as scales giving the affected area of skin a raised and red patchy look. About 2% of population in the US suffers fr...


Editor's Pick
Commercial Roadmap for the Launch: What can Biopharmaceuticals do to Increase...

The Pharma and Biotech Healthcare market has been an ever-changing industry in terms of...

Emerging Market for Organ on a Chip

The organ on a chip is a microfluidic culture device that recapitulates the complicated...

Global Top Players in Intraocular Lens (IOL) Market

 An Intraocular Lens implant is a synthetic, artificial lens placed inside the eye...

Investigating the Pipeline for Ankylosing Spondylitis Treatment Landscape

Ankylosing Spondylitis is a form of arthritis that primarily affects the spine. It caus...

LAG 3: A Promising Next Generation Cancer Immunotherapy

Immunotherapy also called biologic therapy, is a type of cancer treatment that boosts t...

ASCO Conference 2022
ASCO Conference 2022

The American Society of Clinical Oncology is a platform that provides a global connection to researchers, pharma companies, and healthcare professions standing against cancer, finding a cure for it.